Immunological Assessment and Monitoring in Kidney Transplantation
By:
Kevin LouisParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale UMR-S970, University of Paris, Paris, France; and
Kidney Transplant Department, Saint Louis Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

Search for other papers by Kevin Louis in
Current site
Google Scholar
PubMedClose
,
Carmen LefaucheurParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale UMR-S970, University of Paris, Paris, France; and
Kidney Transplant Department, Saint Louis Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

Search for other papers by Carmen Lefaucheur in
Current site
Google Scholar
PubMedClose
, and
Alexandre LoupyParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale UMR-S970, University of Paris, Paris, France; and
Kidney Transplant Department, Necker Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

Search for other papers by Alexandre Loupy in
Current site
Google Scholar
PubMedClose
Volume/Issue:
Volume 21: Issue 3
Published Online:
Aug 2022
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand

Volume 21: Issue 3 (Aug 2022): Transplantation

in Nephrology Self-Assessment Program
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2022 by the American Society of Nephrology 2022
Page Count:
10
Article Category:
Research Article
Print Publication Date:
01 Aug 2022
Published Online:
Aug 2022
  • 1

    Nankivell BJ, Alexander SI: Rejection of the kidney allograft. N Engl J Med 363: 1451–1462, 2010 PubMed

  • 2

    Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378–383, 2004 PubMed

    • Search Google Scholar
    • Export Citation
  • 3

    Loupy A, Vernerey D, Tinel C, Aubert O, Duong van Huyen J-P, Rabant M, et al.: Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 26: 1721–1731, 2015 PubMed

    • Search Google Scholar
    • Export Citation
  • 4

    Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, et al.: T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant 18: 377–390, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 5

    Loupy A, Lefaucheur C: Antibody-mediated rejection of solid-organ allografts. N Engl J Med 379: 1150–1160, 2018 PubMed

  • 6

    Maggiore U, Leventhal J, Cravedi P: Rethinking clinical endpoints in kidney transplant trials. Curr Opin Organ Transplant 25: 1–7, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 7

    Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al.: The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18: 293–307, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 8

    Bestard O, Couzi L, Crespo M, Kessaris N, Thaunat O: Stratifying the humoral risk of candidates to a solid organ transplantation: A proposal of the ENGAGE working group. Transpl Int 34: 1005–1018, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 9

    Terasaki PI, Cai J: Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 86: 377–383, 2008 PubMed

    • Search Google Scholar
    • Export Citation
  • 10

    Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FHJ, et al.: Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95: 19–47, 2013 PubMed

    • Search Google Scholar
    • Export Citation
  • 11

    Konvalinka A, Tinckam K: Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol 26: 1489–1502, 2015 PubMed

  • 12

    Montgomery RA, Tatapudi VS, Leffell MS, Zachary AA: HLA in transplantation. Nat Rev Nephrol 14: 558–570, 2018 PubMed

  • 13

    Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, et al.: Sensitization in transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant 18: 1604–1614, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 14

    Tambur AR, Campbell P, Chong AS, Feng S, Ford ML, Gebel H, et al.: Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. Am J Transplant 20: 2652–2668, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 15

    Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al.: The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20: 2318–2331, 2020

    • Search Google Scholar
    • Export Citation
  • 16

    Senev A, Lerut E, Van Sandt V, Coemans M, Callemeyn J, Sprangers B, et al.: Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. Am J Transplant 19: 3100–3113, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 17

    Dipchand AI, Webber S, Mason K, Feingold B, Bentlejewski C, Mahle WT, et al.; CTOTC-04 Investigators: Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study. Am J Transplant 18: 2163–2174, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 18

    Iasella CJ, Ensor CR, Marrari M, Mangiola M, Xu Q, Nolley E, et al.: Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction. J Heart Lung Transplant 39: 1417–1425, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 19

    Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, et al.: Prevalence, risk factors, and impact of donor-specific alloantibodies after adult liver transplantation. Liver Transpl 24: 1091–1100, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 20

    Huang Y, Dinh A, Heron S, Gasiewski A, Kneib C, Mehler H, et al.: Assessing the utilization of high-resolution 2-field HLA typing in solid organ transplantation. Am J Transplant 19: 1955–1963, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 21

    Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, et al.: Comparison of sequence-specific oligonucleotide probe vs next generation sequencing for HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, and DPB1 typing: Toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs. HLA 94: 296–306, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 22

    Senev A, Emonds M-P, Van Sandt V, Lerut E, Coemans M, Sprangers B, et al.: Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. Am J Transplant 20: 3367–3378, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 23

    Redondo-Pachón D, Pérez-Sáez MJ, Mir M, Gimeno J, Llinás L, García C, et al.: Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes. Hum Immunol 79: 424–431, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 24

    Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al.: Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 23: 2061–2071, 2012 PubMed

    • Search Google Scholar
    • Export Citation
  • 25

    Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, et al.: Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol 28: 702–715, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 26

    Buttigieg J, Ali H, Sharma A, Halawa A: Positive Luminex and negative flow cytometry in kidney transplantation: A systematic review and meta-analysis. Nephrol Dial Transplant 34: 1950–1960, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 27

    Morrison AH, Gupta M, Lloyd K, Trofe-Clark J, Ann Lim M, Limonte C, et al.: Class and kinetics of weakly reactive pretransplant donor-specific HLA antibodies predict rejection in kidney transplant recipients. Transplant Direct 5: e478, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 28

    Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, et al.: Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. Am J Transplant 18: 2274–2284, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 29

    Ziemann M, Altermann W, Angert K, Arns W, Bachmann A, Bakchoul T, et al.: Preformed donor-specific HLA antibodies in living and deceased donor transplantation: A multicenter study. Clin J Am Soc Nephrol 14: 1056–1066, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 30

    Michielsen LA, Wisse BW, Kamburova EG, Verhaar MC, Joosten I, Allebes WA, et al.: A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrol Dial Transplant 34: 1056–1063, 2019

    • Search Google Scholar
    • Export Citation
  • 31

    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, et al.: Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Nephrol Dial Transplant 32: 730–737, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 32

    Lucisano G, Thiruvengadam S, Hassan S, Gueret-Wardle A, Brookes P, Santos-Nunez E, et al.: Donor-specific antibodies detected by single antigen beads alone can help risk stratify patients undergoing retransplantation across a repeat HLA mismatch. Am J Transplant 20: 441–450, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 33

    Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, et al.: Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 9: 2561–2570, 2009 PubMed

    • Search Google Scholar
    • Export Citation
  • 34

    Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, et al.: Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 25: 2267–2277, 2014 PubMed

    • Search Google Scholar
    • Export Citation
  • 35

    Snanoudj R, Kamar N, Cassuto E, Caillard S, Metzger M, Merville P, et al.: Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. Kidney Int 95: 1471–1485, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 36

    Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S: High calcineurin inhibitor intrapatient variability is associated with renal allograft inflammation, chronicity, and graft loss. Transplant Direct 5: e424, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 37

    Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, et al.: Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol 28: 3353–3362, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 38

    Mendoza Rojas A, Hesselink DA, van Besouw NM, Baan CC, van Gelder T: Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients. Expert Rev Clin Immunol 15: 1323–1331, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 39

    Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E, et al.: Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: A validation study in an American cohort. Am J Transplant 21: 322–328, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 40

    Yamamoto T, Watarai Y, Takeda A, Tsujita M, Hiramitsu T, Goto N, et al.: De novo anti-HLA DSA characteristics and subclinical antibody-mediated kidney allograft injury. Transplantation 100: 2194–2202, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 41

    Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, et al.: The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss. Am J Transplant 17: 1574–1584, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 42

    Parajuli S, Reville PK, Ellis TM, Djamali A, Mandelbrot DA: Utility of protocol kidney biopsies for de novo donor-specific antibodies. Am J Transplant 17: 3210–3218, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 43

    Wiebe C, Gareau AJ, Pochinco D, Gibson IW, Ho J, Birk PE, et al.: Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival. Am J Transplant 17: 703–711, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 44

    Bertrand D, Gatault P, Jauréguy M, Garrouste C, Sayegh J, Bouvier N, et al.: Protocol biopsies in patients with subclinical de novo donor-specific antibodies after kidney transplantation: A multicentric study. Transplantation 104: 1726–1737, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 45

    Aubert O, Loupy A, Hidalgo L, Duong van Huyen J-P, Higgins S, Viglietti D, et al.: Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol 28: 1912–1923, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 46

    Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, et al.: Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int 91: 729–737, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 47

    Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT: The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 100: 787–798, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 48

    Callemeyn J, Lerut E, de Loor H, Arijs I, Thaunat O, Koenig A, et al.: Transcriptional changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies. J Am Soc Nephrol 31: 2168–2183, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 49

    Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, et al.: Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. Am J Transplant 19: 763–780, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 50

    Bestard O, Grinyó J: Refinement of humoral rejection effector mechanisms to identify specific pathogenic histological lesions with different graft outcomes. Am J Transplant 19: 952–953, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 51

    Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al.: Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation 104: 911–922, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 52

    Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen J-P, Taupin J-L, et al.: Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J Am Soc Nephrol 29: 606–619, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 53

    Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al.: IgG Endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 377: 442–453, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 54

    Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, et al.: Complement-activating anti-HLA antibodies in kidney transplantation: Allograft gene expression profiling and response to treatment. J Am Soc Nephrol 29: 620–635, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 55

    Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, et al.: Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation. Transplantation 102: 688–698, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 56

    Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, et al.: Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int 94: 773–787, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 57

    Tambur AR, Herrera ND, Haarberg KMK, Cusick MF, Gordon RA, Leventhal JR, et al.: Assessing antibody strength: Comparison of MFI, C1q, and titer information. Am J Transplant 15: 2421–2430, 2015 PubMed

    • Search Google Scholar
    • Export Citation
  • 58

    Gebel HM, Bray RA: A diagnostic ‘C’ saw: The ups and downs of C1q testing. Curr Opin Organ Transplant 24: 402–410, 2019 PubMed

  • 59

    Tambur AR, Schinstock C, Maguire C, Lowe D, Smith B, Stegall M: Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. Am J Transplant 21: 1278–1284, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 60

    Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, et al.: Prediction system for risk of allograft loss in patients receiving kidney transplants: International derivation and validation study. BMJ 366: l4923, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 61

    Aubert O, Divard G, Pascual J, Oppenheimer F, Sommerer C, Citterio F, et al.: Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: Proof-of-concept study. BMJ Open 11: e052138, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 62

    Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana J-P, et al.: Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLoS Med 15: e1002572, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 63

    Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, et al.: Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival. J Am Soc Nephrol 27: 615–625, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 64

    Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, et al.: Pretransplant C3d-fixing donor-specific anti-HLA antibodies are not associated with increased risk for kidney graft failure. J Am Soc Nephrol 29: 2279–2285, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 65

    Calp-Inal S, Ajaimy M, Melamed ML, Savchik C, Masiakos P, Colovai A, et al.: The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation. Kidney Int 89: 209–216, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 66

    Comoli P, Cioni M, Tagliamacco A, Quartuccio G, Innocente A, Fontana I, et al.: Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients. Am J Transplant 16: 2106–2116, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 67

    Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen J-P, Vernerey D, Aubert O, et al.: IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 27: 293–304, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 68

    Thomas KA, Valenzuela NM, Reed EF: The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med 21: 319–329, 2015 PubMed

    • Search Google Scholar
    • Export Citation
  • 69

    Jackson AM, Kanaparthi S, Burrell BE, Lucas DP, Vega RM, Demetris AJ, et al.: IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients. Am J Transplant 20: 513–524, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 70

    Jackson AM, Sigdel TK, Delville M, Hsieh S-C, Dai H, Bagnasco S, et al.: Endothelial cell antibodies associated with novel targets and increased rejection. J Am Soc Nephrol 26: 1161–1171, 2015 PubMed

    • Search Google Scholar
    • Export Citation
  • 71

    Grafft CA, Cornell LD, Gloor JM, Cosio FG, Gandhi MJ, Dean PG, et al.: Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 25: 307–310, 2010

    • Search Google Scholar
    • Export Citation
  • 72

    Kalil J, Guilherme L, Neumann J, Rosales C, Marin M, Saldanha L, et al.: Humoral rejection in two HLA identical living related donor kidney transplants. Transplant Proc 21: 711–713, 1989 PubMed

    • Search Google Scholar
    • Export Citation
  • 73

    Dragun D, Catar R, Philippe A: Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. Kidney Int 90: 280–288, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 74

    Pineda S, Sigdel TK, Chen J, Jackson AM, Sirota M, Sarwal MM: Novel non-histocompatibility antigen mismatched variants improve the ability to predict antibody-mediated rejection risk in kidney transplant. Front Immunol 8: 1687, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 75

    Zhang Q, Reed EF: The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol 12: 484–495, 2016 PubMed

  • 76

    Cardinal H, Dieudé M, Hébert M-J: The emerging importance of non-HLA autoantibodies in kidney transplant complications. J Am Soc Nephrol 28: 400–406, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 77

    Zorn E, See SB: Is there a role for natural antibodies in rejection following transplantation? Transplantation 103: 1612–1619, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 78

    Sun Q, Cheng Z, Cheng D, Chen J, Ji S, Wen J, et al.: De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection [published expression of concern in Kidney Int 96: 795, 2019]. Kidney Int 79: 655–662, 2011 PubMed

    • Search Google Scholar
    • Export Citation
  • 79

    Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, et al.: Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens. J Am Soc Nephrol 30: 692–709, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 80

    Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al.: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352: 558–569, 2005 PubMed

    • Search Google Scholar
    • Export Citation
  • 81

    Yu S, Huh HJ, Lee KW, Park JB, Kim S-J, Huh W, et al.: Pre-transplant angiotensin II type 1 receptor antibodies and anti-endothelial cell antibodies predict graft function and allograft rejection in a low-risk kidney transplantation setting. Ann Lab Med 40: 398–408, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 82

    Min JW, Lee H, Choi BS, Park CW, Yang CW, Kim YS, et al.: Clinical impact of pre-transplant antibodies against angiotensin II type I receptor and major histocompatibility complex class I-related chain A in kidney transplant patients. Ann Lab Med 38: 450–457, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 83

    Philogene MC, Zhou S, Lonze BE, Bagnasco S, Alasfar S, Montgomery RA, et al.: Pre-transplant screening for non-HLA antibodies: Who should be tested? Hum Immunol 79: 195–202, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 84

    Pearl MH, Zhang Q, Palma Diaz MF, Grotts J, Rossetti M, Elashoff D, et al.: Angiotensin II type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. Kidney Int 93: 260–269, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 85

    Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, et al.: Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int 96: 189–201, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 86

    Pinelli DF, Friedewald JJ, Haarberg KMK, Radhakrishnan SL, Zitzner JR, Hanshew WE, et al.: Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. Hum Immunol 78: 421–427, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 87

    Gareau AJ, Wiebe C, Pochinco D, Gibson IW, Ho J, Rush DN, et al.: Pre-transplant AT1R antibodies correlate with early allograft rejection. Transpl Immunol 46: 29–35, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 88

    Fichtner A, Süsal C, Schröder C, Höcker B, Rieger S, Waldherr R, et al.: Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. Nephrol Dial Transplant 33: 1065–1072, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 89

    Pearl MH, Chen L, ElChaki R, Elashoff D, Gjertson DW, Rossetti M, et al.: Endothelin type A receptor antibodies are associated with angiotensin II type 1 receptor antibodies, vascular inflammation, and decline in renal function in pediatric kidney transplantation. Kidney Int Rep 5: 1925–1936, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 90

    Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al.: The Banff 2015 Kidney Meeting Report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant 17: 28–41, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 91

    Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen J-P, Suberbielle C, Anglicheau D, et al.: Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 381: 313–319, 2013 PubMed

    • Search Google Scholar
    • Export Citation
  • 92

    Dragun D, Philippe A, Catar R, Hegner B: Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost 101: 643–648, 2009 PubMed

    • Search Google Scholar
    • Export Citation
  • 93

    Fichtner A, Süsal C, Höcker B, Rieger S, Waldherr R, Westhoff JH, et al.: Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients. Pediatr Nephrol 36: 2473–2484, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 94

    Crespo M, Llinàs-Mallol L, Redondo-Pachón D, Butler C, Gimeno J, Pérez-Sáez MJ, et al.: Non-HLA antibodies and epitope mismatches in kidney transplant recipients with histological antibody-mediated rejection. Front Immunol 12: 703457, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 95

    Butler CL, Hickey MJ, Jiang N, Zheng Y, Gjertson D, Zhang Q, et al.: Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. Am J Transplant 20: 2768–2780, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 96

    See SB, Mantell BS, Clerkin KJ, Ray B, Vasilescu ER, Marboe CC, et al.: Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation. Am J Transplant 20: 2571–2580, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 97

    Zhang X, Levine R, Patel JK, Kittleson M, Czer L, Kobashigawa JA: Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients. Hum Immunol 81: 671–674, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 98

    Riesco L, Irure J, Rodrigo E, Guiral S, Ruiz JC, Gómez J, et al.: Anti-perlecan antibodies and acute humoral rejection in hypersensitized patients without forbidden HLA specificities after kidney transplantation. Transpl Immunol 52: 53–56, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 99

    Betjes MGH, Sablik KA, Litjens NHR, Otten HG, de Weerd AE: ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts. Hum Immunol 82: 89–96, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 100

    Senev A, Otten HG, Kamburova EG, Callemeyn J, Lerut E, Van Sandt V, et al.: Antibodies against ARHGDIB and ARHGDIB gene expression associate with kidney allograft outcome. Transplantation 104: 1462–1471, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 101

    Kamburova EG, Gruijters ML, Kardol-Hoefnagel T, Wisse BW, Joosten I, Allebes WA, et al.: Antibodies against ARHGDIB are associated with long-term kidney graft loss. Am J Transplant 19: 3335–3344, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 102

    De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al.: Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 6: 241ra77, 2014 PubMed

    • Search Google Scholar
    • Export Citation
  • 103

    Oellerich M, Sherwood K, Keown P, Schütz E, Beck J, Stegbauer J, et al.: Liquid biopsies: Donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol 17: 591–603, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 104

    Garg N, Mandelbrot DA, Parajuli S, Aziz F, Astor BC, Chandraker A, et al.: The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplant Rev (Orlando) 35: 100649, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 105

    Filippone EJ, Farber JL: The monitoring of donor-derived cell-free DNA in kidney transplantation. Transplantation 105: 509–516, 2021 PubMed

    • Search Google Scholar
    • Export Citation
  • 106

    Gielis EM, Beirnaert C, Dendooven A, Meysman P, Laukens K, De Schrijver J, et al.: Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. PLoS One 13: e0208207, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 107

    Knight SR, Thorne A, Lo Faro ML: Donor-specific cell-free DNA as a biomarker in solid organ transplantation. A Systematic Review. Transplantation 103: 273–283, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 108

    Wijtvliet VPWM, Plaeke P, Abrams S, Hens N, Gielis EM, Hellemans R, et al.: Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: A systematic review and meta-analysis. Transpl Int 33: 1626–1642, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 109

    Jordan SC, Bunnapradist S, Bromberg JS, Langone AJ, Hiller D, Yee JP, et al.: Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients. Transplant Direct 4: e379, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 110

    Bu L, Gupta G, Pai A, Anand S, Stites E, Moinuddin I, et al.: Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int 101: 793–803, 2022

    • Search Google Scholar
    • Export Citation
  • 111

    Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Billings P; Trifecta Investigators: The Trifecta Study: Comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol 33: 387–400, 2022 PubMed

    • Search Google Scholar
    • Export Citation
  • 112

    Oellerich M, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, et al.: Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant 19: 3087–3099, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 113

    Gielis EM, Ledeganck KJ, Dendooven A, Meysman P, Beirnaert C, Laukens K, et al.: The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation. Nephrol Dial Transplant 35: 714–721, 2020

    • Search Google Scholar
    • Export Citation
  • 114

    Hirt-Minkowski P, De Serres SA, Ho J: Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection. Can J Kidney Health Dis 2: 28, 2015 PubMed

    • Search Google Scholar
    • Export Citation
  • 115

    Anglicheau D, Naesens M, Essig M, Gwinner W, Marquet P: Establishing biomarkers in transplant medicine: A critical review of current approaches. Transplantation 100: 2024–2038, 2016 PubMed

    • Search Google Scholar
    • Export Citation
  • 116

    Guzzi F, Cirillo L, Buti E, Becherucci F, Errichiello C, Roperto RM, et al.: Urinary biomarkers for diagnosis and prediction of acute kidney allograft rejection: A systematic review. Int J Mol Sci 21: E6889, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 117

    Rabant M, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V, Bonifay R, Morin L, Scemla A, Delville M, Martinez F, Timsit MO, Duong Van Huyen J-P, Legendre C, Terzi F, Anglicheau D: Urinary C-X-C motif chemokine 10 independently improves the noninvasive diagnosis of antibody–mediated kidney allograft rejection. JASN 26: 2840–2851, 2015

    • Search Google Scholar
    • Export Citation
  • 118

    Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, et al.; CTOT-01 consortium: Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 13: 2634–2644, 2013 PubMed

    • Search Google Scholar
    • Export Citation
  • 119

    Ho J, Sharma A, Kroeker K, Carroll R, De Serres S, Gibson IW, et al.: Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. BMJ Open 9: e024908, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 120

    Sigdel TK, Yang JYC, Bestard O, Schroeder A, Hsieh S-C, Liberto JM, et al.: A urinary common rejection module (uCRM) score for non-invasive kidney transplant monitoring. PLoS One 14: e0220052, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 121

    Yang JYC, Sarwal RD, Sigdel TK, Damm I, Rosenbaum B, Liberto JM, et al.: A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection. Sci Transl Med 12: eaba2501, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 122

    Tinel C, Devresse A, Vermorel A, Sauvaget V, Marx D, Avettand-Fenoel V, et al.: Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. Am J Transplant 20: 3462–3476, 2020 PubMed

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 628 627 43
Full Text Views 749 749 53
PDF Downloads 962 962 55